



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/980,242	11/29/2001	Erwin Bischoff	Le A 33 535	1312

7590 03/31/2003

Jeffrey M Greenman  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

EXAMINER

ANDERSON, REBECCA L

ART UNIT PAPER NUMBER

1626

10

DATE MAILED: 03/31/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	09/980,242	BISCHOFF ET AL.
	Examiner Rebecca L Anderson	Art Unit 1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on \_\_\_\_\_.  
 2a) This action is FINAL.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-6,8-16 and 21-62 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_ is/are allowed.  
 6) Claim(s) \_\_\_\_ is/are rejected.  
 7) Claim(s) \_\_\_\_ is/are objected to.  
 8) Claim(s) 1-6,8-16 and 21-62 are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 11) The proposed drawing correction filed on \_\_\_\_ is: a) approved b) disapproved by the Examiner.  
     If approved, corrected drawings are required in reply to this Office action.  
 12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All b) Some \* c) None of:  
     1. Certified copies of the priority documents have been received.  
     2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
     3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
     \* See the attached detailed Office action for a list of the certified copies not received.  
 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
     a) The translation of the foreign language provisional application has been received.  
 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____. .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. .	6) <input type="checkbox"/> Other: _____

## DETAILED ACTION

Claims 1-6, 8-16 and 21-62 are currently pending in the instant application.

### ***Election/Restrictions***

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Due to the numerous variables in the claims, e.g., A, D, E, G, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, L<sup>1</sup>, L<sup>2</sup>, T, etc. in the claims and their widely divergent meanings, a precise listing of inventive groups cannot be made. The following groups are exemplary:

Group I, claims 1-6, 8, 16 and 21-62 drawn to products of the formula I, wherein A is CH, D is CH, E is CH, G is CH, R<sup>1</sup> is CO-NR<sup>4</sup>R<sup>5</sup>, R<sup>2</sup> is morpholinyl substituted by one to three hydroxyl groups and/or by a radical of the formula –NR<sub>8</sub>R<sub>9</sub>, R<sup>3</sup> is phenyl optionally substituted as found in claim 1, L<sup>1</sup>, L<sup>2</sup>, R<sup>4</sup>, and R<sup>5</sup> are as in claim 1, R<sup>8</sup> and R<sup>9</sup> are identical or different and each represents hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl, and processes for their preparation, and their methods of use.

Group II, claims 1-6, 8, 16 and 21-62 drawn to products of the formula I, wherein A is CH, D is CH, E is CH, G is nitrogen, R<sup>1</sup> is CO-NR<sup>4</sup>R<sup>5</sup>, R<sup>2</sup> is morpholinyl substituted by one to three hydroxyl groups and/or by a radical of the formula –NR<sub>8</sub>R<sub>9</sub>, R<sup>3</sup> is phenyl optionally substituted as found in claim 1, L<sup>1</sup>, L<sup>2</sup>, R<sup>4</sup>, and R<sup>5</sup> are as in claim 1, R<sup>8</sup> and R<sup>9</sup> are identical or different and each represents hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl, and processes for their preparation, and their methods of use.

Group III, claims 1-6, 8, 16 and 21-62 drawn to products of the formula I, wherein

A is CH, D is CH, E is CH, G is nitrogen, R<sup>1</sup> is CO-NR<sup>4</sup>R<sup>5</sup>, R<sup>2</sup> is piperazinyl substituted by one to three hydroxyl groups and/or by a radical of the formula -NR<sub>8</sub>R<sub>9</sub>, R<sup>3</sup> is phenyl optionally substituted as found in claim 1, L<sup>1</sup>, L2, R4, and R5 are as in claim 1, R8 and R9 are identical or different and each represents hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl, and processes for their preparation, and their methods of use.

Group IV, claims 1-6, 8, 16 and 21-62 drawn to products of the formula I, wherein A is CH, D is CH, E is CH, G is CH, R<sup>1</sup> is CO-NR<sup>4</sup>R<sup>5</sup>, R<sup>2</sup> is piperazinyl substituted by one to three hydroxyl groups and/or by a radical of the formula -NR<sub>8</sub>R<sub>9</sub>, R<sup>3</sup> is phenyl optionally substituted as found in claim 1, L<sup>1</sup>, L2, R4, and R5 are as in claim 1, R8 and R9 are identical or different and each represents hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl, and processes for their preparation, and their methods of use.

Group V, claims 9, 10, 12 and 13 drawn to compounds of the formulas IV, V, IX and X wherein A is CH, D is CH, E is CH, G is CH, R<sup>11</sup> or -N12R13 is a piperazinyl substituted by one to three hydroxyl groups and/or hydroxyl protective groups and/or by a radical of the formula -NR<sub>8</sub>R<sub>9</sub> and/or by an amino protective group, R8 and R9 are identical or different and each represents hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl, L<sup>1</sup> and L2 are as found in claim 1, and T is as found in claim 8.

Group VI, claims 9, 10, 12 and 13 drawn to compounds of the formulas IV, V, IX and X wherein A is CH, D is CH, E is CH, G is nitrogen, R<sup>11</sup> or -N12R13 is a piperazinyl substituted by one to three hydroxyl groups and/or hydroxyl protective groups and/or by a radical of the formula -NR<sub>8</sub>R<sub>9</sub> and/or by an amino protective group, R8 and R9 are

identical or different and each represents hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl, L<sup>1</sup> and L<sup>2</sup> are as found in claim 1, and T is as found in claim 8.

Group VII, claim 11 drawn to compounds of the formula VII wherein A is CH, D is CH, E is CH, G is CH, L<sup>1</sup> and L<sup>2</sup> are as found in claim 1, T is as found in claim 8, and Y is mesyl.

Group VIII, claim 11 drawn to compounds of the formula VII wherein A is CH, D is CH, E is CH, G is nitrogen, L<sup>1</sup> and L<sup>2</sup> are as found in claim 1, T is as found in claim 8, and Y is halogen.

Group IX, claim 14 drawn to (S)-(4-Fluorophenyl)glycinamide and its salts.

Group X, claim 15 drawn to (S)-(3-Pyridyl)glycinamide and its salts.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Again, this list is not exhausted as it would be impossible under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, applicant may choose to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention and examiner will endeavor to group the same.

The claims herein lack unity of invention under PCT rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The technical feature of claims 14 and 15 differ from each other and from the compounds of claims 1-6, 8-13, 16 and 21-62. Also, the compounds in claims 1-6, 8-13, 16 and 21-62 all contain a cyclohexyl benzimidazole, which does not define a contribution over the prior

art (as can be seen by the compounds on page 4 of EP 0 725 064 A1). The substituents on the cyclohexyl benzimidazole vary extensively and when taken as a whole result in vastly different compounds. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper. Additionally, the vastness of the claimed subject matter, and the complications in understanding the claimed subject matter imposes a burden on any examination of the claimed subject matter.

### **Conclusion**

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (703) 605-1157. Mrs. Anderson can normally be reached Monday through Friday 7:00AM to 3:30PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph McKane, can be reached at (703) 308-4537.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone numbers are (703) 308-1235 and (703) 308-0196.

Application/Control Number: 09/980,242  
Art Unit: 1626


Page 6

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45AM to 4:45PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4242, (703) 305-3592, and (703) 305-3014.



---

Rebecca Anderson  
Patent Examiner  
Art Unit 1626, Group 1620  
Technology Center 1600



---

Joseph McKane  
Supervisory Patent Examiner  
Art Unit 1626, Group 1620  
Technology Center 1600